SRC and amyotrophic lateral sclerosis: They also found that bosutinib, one of the specific Src/c-Abl inhibitors, could modestly extend the survival of the SOD1 mutation mouse model of ALS, suggesting that Src/c-Abl may be a potential target for developing new drugs to treat ALS (Imamura et al., 2017).